for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inflarx NV

IFRX.OQ

Latest Trade

2.20USD

Change

-0.15(-6.38%)

Volume

105,514

Today's Range

2.18

 - 

2.34

52 Week Range

2.17

 - 

52.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Inflarx Reports Cash And Cash Equivalents Plus Securities And Other Investments Of EUR 138.3 Million As Of June 30

Aug 14 (Reuters) - Inflarx NV <IF0G.F>::INFLARX REPORTS SECOND QUARTER 2019 FINANCIAL & OPERATING RESULTS.CASH AND CASH EQUIVALENTS PLUS SECURITIES AND OTHER INVESTMENTS OF EUR 138.3 MILLION AS OF JUNE 30, 2019.H1 LOSS PER SHARE EUR 0.97.Q2 EARNINGS PER SHARE VIEW EUR -0.47 -- REFINITIV IBES DATA.

InflaRx Reports Additional Analysis Of The SHINE Phase IIb Results For IFX-1 In Hidradenitis Suppurativa

July 18 (Reuters) - Inflarx NV <IF0G.F>::INFLARX REPORTS ADDITIONAL ANALYSIS OF THE SHINE PHASE IIB RESULTS FOR IFX-1 IN HIDRADENITIS SUPPURATIVA.INFLARX NV - IFX-1 TREATMENT IN HIGH DOSE GROUP RESULTED IN MULTIPLE EFFICACY SIGNALS SUPPORTING FURTHER DEVELOPMENT OF IFX-1 IN HS.INFLARX NV - IFX-1 SUPPRESSED C5A LEVELS DOSE DEPENDENTLY AND EXHIBITED A FAVORABLE SAFETY PROFILE WITH LOW ANTI-DRUG ANTIBODY RATES.INFLARX NV - OPEN-LABEL EXTENSION STUDY IS ONGOING, INFLARX PLANS END OF PHASE II REGULATORY DISCUSSIONS AFTER COMPLETION OF SHINE TRIAL.

Inflarx NV Files For Potential Mixed Shelf Offering; Size Not Disclosed

March 28 (Reuters) - Inflarx NV <IFRX.O>::INFLARX NV FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Inflarx NV Had Cash & Cash Equivalents & Securities & Other Investments Of EUR 156.6 Mln As Of Dec. 31, 2018

March 28 (Reuters) - Inflarx NV <IFRX.O>::INFLARX FULL YEAR 2018 FINANCIAL & OPERATING RESULTS.INFLARX NV - AS OF DECEMBER 31, 2018, INFLARX HAD CASH AND CASH EQUIVALENTS AND SECURITIES AND OTHER INVESTMENTS OF EUR 156.6 MILLION.

Inflarx Announces Presentation Of New Clinical Data With Lead Candidate Ifx-1 In Hidradenitis Suppurativa

Feb 6 (Reuters) - Inflarx NV <IFRX.O>::INFLARX ANNOUNCES PRESENTATION OF NEW CLINICAL DATA WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA.INFLARX NV - RETROSPECTIVE LONG-TERM RESULTS FROM PHASE IIA TRIAL INDICATE SUSTAINED REMISSION POST IFX-1 TREATMENT.INFLARX NV - BASELINE CHARACTERISTICS FROM ONGOING PHASE IIB SHINE TRIAL IN LINE WITH EXPECTATIONS; ON TRACK FOR TOPLINE RESULTS Q2 2019.

Inflarx N.V. Reports Third Quarter 2018 Financial & Operating Results

Nov 21 (Reuters) - Inflarx NV <IFRX.O>::INFLARX N.V. REPORTS THIRD QUARTER 2018 FINANCIAL & OPERATING RESULTS.Q3 LOSS PER SHARE EUR 0.30.Q3 EARNINGS PER SHARE VIEW EUR -0.36 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS AND SECURITIES AND OTHER INVESTMENTS OF EUR 162.1 MILLION.

Inflarx NV Q2 Loss Per Share EUR 0.10

Aug 9 (Reuters) - Inflarx NV <IFRX.O>::INFLARX N.V. REPORTS SECOND QUARTER 2018 FINANCIAL & OPERATING RESULTS.Q2 LOSS PER SHARE EUR 0.10.Q2 EARNINGS PER SHARE VIEW EUR -0.34 -- THOMSON REUTERS I/B/E/S.CASH POSITION APPROXIMATELY EUR 156.1 MILLION (US$182.2 MILLION) AS OF JUNE 30, 2018.

InflaRx Receives IND Approval From FDA To Start Phase II Clinical Trial Of IFX-1

June 28 (Reuters) - Inflarx NV <IFRX.O>::INFLARX RECEIVES IND APPROVAL FROM THE FDA TO START ITS PHASE II CLINICAL TRIAL OF IFX-1 IN ANCA-ASSOCIATED VASCULITIS.INFLARX NV - OPEN IND WILL ALLOW INFLARX TO START PLANNED PHASE II STUDY TO DETERMINE SAFETY AND EFFICACY OF IFX-1.

Inflarx N.V. Reports Q1 Loss Per Share Eur 0.40

May 17 (Reuters) - Inflarx NV <IFRX.O>::INFLARX N.V. REPORTS FIRST QUARTER 2018 FINANCIAL & OPERATING RESULTS.Q1 LOSS PER SHARE EUR 0.40.CASH POSITION APPROXIMATELY US$137 MILLION (EUR 115 MILLION) AS OF MARCH 31, 2018.

Inflarx NV Files For Offering Of Up To 1.5 Mln Common Shares

May 2 (Reuters) - Inflarx NV <IFRX.O>::INFLARX NV FILES FOR OFFERING OF UP TO 1.5 MILLION COMMON SHARES AND SELLING SHAREHOLDERS OFFERING UP TO 1.5 MILLION COMMON SHARES - SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up